No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Daan Gene Co., Ltd. specializes in the research, development, manufacturing, and commercialization of clinical diagnostic reagents and instruments. The company's extensive product portfolio encompasses advanced solutions such as fluorescence quantitative PCR products, time-resolved series diagnostics, enzyme-linked immunoassay (EIA) kits, various diagnostic instruments, and specialized scientific research services. Beyond product offerings, the company extends its expertise to provide comprehensive medical examination and health management services. These encompass a wide range of offerings, from genetic susceptibility gene testing and tumor marker analysis to crucial cervical cancer screening and general routine physical examinations, alongside other personalized health support. Established in 2001, the company was originally known as Da An Gene Co., Ltd. of Sun Yat-Sen University. It is presently headquartered in Guangzhou, located in the People's Republic of China.
www.daangene.comNo one on the platform currently holds 002030.SZ.
No tracked institution reports a position in 002030.SZ as of their last filing.
No one on the platform has traded 002030.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -11.2% | -32.3% | ||||
| Profit Margin % | -98.2% | -21.1% | -3.2% | |||
| Free Cash Flow Margin % | 10.6% | 19.9% | 9.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.4B | +0.0% | $0.11 | $0.11–$0.11 | — | 1 |
| 2027 | $753M | -68.6% | $0.16 | $0.16–$0.16 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 002030.SZDaan Gene Co., Ltd. | $5.24 | +0.38% | $7.4B | — |
| 000999.SZChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd. | $23.88 | +0.17% | $39.7B | — |
| 002001.SZZhejiang NHU Company Ltd. | $26.24 | -0.08% | $80.6B | — |
| 002007.SZHualan Biological Engineering Inc. | $12.71 | -0.24% | $23.2B | — |
| 002022.SZShanghai Kehua Bio-engineering Co., Ltd. | $5.56 | -0.18% | $2.9B | — |
| 4162.TWOPharmaEngine, Inc. | $55.50 | +1.65% | $8.0B | — |
| 6547.TWOMedigen Vaccine Biologics Corp. | $60.80 | +0.50% | $20.0B | — |
Source: Financial Modeling Prep · peers by sector/industry